Codexis Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis or view top-rated stocks.

Wall Street analysts have given Codexis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Codexis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, February, 25th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.07. Codexis had a negative trailing twelve-month return on equity of 21.25% and a negative net margin of 31.08%.
View Codexis' earnings history.

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 92.8% and is now trading at $19.51.
View which stocks have been most impacted by COVID-19.

Codexis updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $82-85 million, compared to the consensus revenue estimate of $80.53 million.

4 brokers have issued 12 month price targets for Codexis' stock. Their forecasts range from $16.00 to $30.00. On average, they anticipate Codexis' share price to reach $25.25 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for Codexis or view top-rated stocks among Wall Street analysts.

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of CDXS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.78%), BlackRock Inc. (7.93%), Wells Fargo & Company MN (3.91%), William Blair Investment Management LLC (3.63%), Janus Henderson Group PLC (2.40%) and Sumitomo Mitsui Trust Holdings Inc. (1.43%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Assenagon Asset Management S.A., Janus Henderson Group PLC, Wells Fargo & Company MN, Aviva PLC, Trigran Investments Inc., William Blair Investment Management LLC, and Overbrook Management Corp. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, and Thomas R Baruch.
View insider buying and selling activity for Codexis or view top insider-selling stocks.

CDXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, Avidity Partners Management LP, Baillie Gifford & Co., Pura Vida Investments LLC, Asymmetry Capital Management L.P., Monashee Investment Management LLC, and Nikko Asset Management Americas Inc.. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis or or view top insider-buying stocks.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $19.51.

Codexis has a market capitalization of $1.16 billion and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

Codexis employs 161 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]